Cumberland Pharmaceuticals INC Form 4 insider transactions

Director Caroline Young continues to increase her holdings in Cumberland Pharmaceuticals through a pre-arranged Rule 10b5-1 trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has been consistently acquiring shares of the company's common stock through a pre-arranged 10b5-1 trading plan.

Kenneth Krogulski, a director of Cumberland Pharmaceuticals, acquired 5,000 shares of common stock at a price of $1.71 per share on March 25, 2024.

Director James Jones of Cumberland Pharmaceuticals Inc. reports acquiring 1,000 shares of common stock at $1.71 per share on March 25, 2024.

Joseph C. Galante, a director of Cumberland Pharmaceuticals, acquired 1,000 shares of common stock at a price of $1.71 per share on March 25, 2024.

Director Caroline Young acquired 1,000 shares of Cumberland Pharmaceuticals stock at $1.71 per share on March 25, 2024.

Director Martin S. Brown Jr. acquired 1,000 shares of Cumberland Pharmaceuticals Inc. common stock at a price of $1.71 per share on March 25, 2024.

Cumberland Pharmaceuticals' CEO, A.J. Kazimi, reports the withholding of shares to cover tax obligations related to vesting shares and the acquisition of options.

VP and Chief Compliance Officer of Cumberland Pharmaceuticals, James L. Herman, reports the disposition of shares to cover tax obligations and acquisition of options.

Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals, reports the acquisition and disposal of company stock to cover tax obligations and the acquisition of options.

Todd M. Anthony, Vice President of Organizational Development at Cumberland Pharmaceuticals, reports a transaction involving common stock and options.

Cumberland Pharmaceuticals' VP and CFO, John Hamm, reports the disposition of shares to cover tax obligations and the acquisition of options.